{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:06:34Z","timestamp":1791353194193,"version":"4.3.1"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:00:00Z","timestamp":1585008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2020.00333","type":"journal-article","created":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T04:45:43Z","timestamp":1585025143000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":46,"title":["Both Pharmacokinetic Variability and Granuloma Heterogeneity Impact the Ability of the First-Line Antibiotics to Sterilize Tuberculosis Granulomas"],"prefix":"10.3389","volume":"11","author":[{"given":"Joseph M.","family":"Cicchese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Dartois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise E.","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Linderman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,3,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.ijantimicag.2005.05.005","article-title":"Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis","volume":"26","author":"Bhusal","year":"2005","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1084\/jem.20180518","article-title":"Impact of immunopathology on the antituberculous activity of pyrazinamide","volume":"215","author":"Blanc","year":"2018","journal-title":"J. Exp. Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"5237","DOI":"10.1073\/pnas.88.12.5237","article-title":"Molecular mechanism of slow acetylation of drugs and carcinogens in humans","volume":"88","author":"Blum","year":"1991","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(16)30274-2","article-title":"High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial","volume":"17","author":"Boeree","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/cid\/cix247","article-title":"Comparing the Efficacy of Drug Regimens for Pulmonary Tuberculosis: Meta-analysis of Endpoints in Early-Phase Clinical Trials","volume":"65","author":"Bonnett","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"872","DOI":"10.15252\/msb.20156777","article-title":"Chemogenomics and orthology-based design of antibiotic combination therapies","volume":"12","author":"Chandrasekaran","year":"2016","journal-title":"Mol. Syst. Biol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s12195-017-0507-6","article-title":"Applying Optimization Algorithms to Tuberculosis Antibiotic Treatment Regimens","volume":"10","author":"Cicchese","year":"2017","journal-title":"Cell. Mol. Bioeng."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0068680","article-title":"Multi-scale modeling predicts a balance of tumor necrosis factor-a and interleukin-10 controls the granuloma environment during Mycobacterium truberculosis infection","volume":"8","author":"Cilfone","year":"2013","journal-title":"PloS One"},{"key":"B9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s12195-014-0363-6","article-title":"Strategies for Efficient Numerical Implementation of Hybrid Multi-scale Agent-Based Models to Describe Biological Systems","volume":"8","author":"Cilfone","year":"2015","journal-title":"Cell. Mol. Bioeng."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1701881","article-title":"Efficient measurement and factorization of high-order drug interactions in Mycobacterium tuberculosis","volume":"3","author":"Cokol","year":"2017","journal-title":"Sci. Adv."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pcbi.1006677","article-title":"Chemogenomic model identifies synergistic drug combinations robust to the pathogen microenvironment","volume":"14","author":"Cokol","year":"2018","journal-title":"PloS Comput. Biol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/nrmicro3200","article-title":"The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells","volume":"12","author":"Dartois","year":"2014","journal-title":"Nat. Rev. Microbiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0141002","article-title":"Pharmacokinetics of isoniazid, pyrazinamide, and ethambutol in newly diagnosed pulmonary TB patients in Tanzania","volume":"10","author":"Denti","year":"2015","journal-title":"PloS One"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1128\/AAC.01474-06","article-title":"Early Bactericidal Activity of High-Dose Rifampin in Patients with Pulmonary Tuberculosis Evidenced by Positive Sputum Smears","volume":"51","author":"Diacon","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"B15","doi-asserted-by":"publisher","first-page":"S75","DOI":"10.1016\/S1472-9792(08)70038-6","article-title":"The early bactericidal activity of anti-tuberculosis drugs: a literature review","volume":"88","author":"Donald","year":"2008","journal-title":"Tuberculosis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.4049\/jimmunol.1003299","article-title":"Multiscale computational modeling reveals a critical role for TNF-\u03b1 receptor 1 dynamics in tuberculosis granuloma formation","volume":"186","author":"Fallahi-Sichani","year":"2011","journal-title":"J. Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis","volume":"371","author":"Gillespie","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B18","year":"2018"},{"key":"B19","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.tube.2006.12.001","article-title":"Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein","volume":"87","author":"Hartkoorn","year":"2007","journal-title":"Tuberculosis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1021\/acsinfecdis.5b00127","article-title":"Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB\/FeJ Mice","volume":"2","author":"Irwin","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1128\/AAC.47.7.2118","article-title":"Pharmacokinetics-Pharmacodynamics of Rifampin in an Aerosel Infection Model of Tuberculosis","volume":"47","author":"Jayaram","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1128\/AAC.48.8.2951-2957.2004","article-title":"Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis","volume":"48","author":"Jayaram","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1164\/rccm.200210-1125OC","article-title":"Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days","volume":"167","author":"Jindani","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1314210","article-title":"High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis","volume":"371","author":"Jindani","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"4230","DOI":"10.1128\/AAC.00274-11","article-title":"Population pharmacokinetics of ethambutol in South African tuberculosis patients","volume":"55","author":"Jonsson","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1128\/AAC.49.5.1733","article-title":"Should We Use N-Acetyltransferase Type 2 Genotyping To Personalize Isoniazid Doses","volume":"49","author":"Kinzig-Schippers","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"B27","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1128\/AAC.05208-11","article-title":"Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions","volume":"56","author":"Kjellsson","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"B28","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/jac\/dku457","article-title":"Comprehensive physicochemical, pharmacokinetic and activity profiling of anti-TB agents","volume":"70","author":"Lakshminarayana","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"B29","doi-asserted-by":"publisher","first-page":"5181","DOI":"10.1128\/AAC.00462-15","article-title":"Population modeling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs","volume":"59","author":"Lalande","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1128\/AAC.02637-15","article-title":"Sterilizing activity of pyrazinamide in combination with first-line drugs in a C3HeB\/FeJ mouse model of tuberculosis","volume":"60","author":"Lanoix","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"B31","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1039\/C4IB00295D","article-title":"A multi-scale approach to designing therapeutics for tuberculosis","volume":"7","author":"Linderman","year":"2015","journal-title":"Integr. Biol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/mBio.02627-19","article-title":"Transcriptomic signatures predict regulators of drug synergy and clinical regimen efficacy against tuberculosis","volume":"10","author":"Ma","year":"2019","journal-title":"MBio"},{"key":"B33","doi-asserted-by":"publisher","first-page":"S349","DOI":"10.1093\/cid\/ciy623","article-title":"Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration from Preclinical Models to Patients with Tuberculosis: Translating from Apples to Oranges","volume":"67","author":"Magombedze","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jtbi.2008.04.011","article-title":"A methodology for performing global uncertainty and sensitivity analysis in systems biology","volume":"254","author":"Marino","year":"2008","journal-title":"J. Theor. Biol."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1862-y","article-title":"Does directly observed therapy improve tuberculosis treatment? More evidence is needed to guide tuberculosis policy","volume":"16","author":"McLaren","year":"2016","journal-title":"BMC Infect. Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1371\/journal.pmed.0040238","article-title":"Patient Adherence to Tuberculosis Treatment: A Systematic Review of Qualitative Research","volume":"4","author":"Munro","year":"2007","journal-title":"PloS Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1093\/cid\/ciw566","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B38","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/imr.12275","article-title":"TB drug development: Immunology at the table","volume":"264","author":"Nathan","year":"2015","journal-title":"Immunol. Rev."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.00038-17","article-title":"Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis","volume":"61","author":"Peloquin","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"B40","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jtbi.2014.11.021","article-title":"A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment","volume":"367","author":"Pienaar","year":"2015","journal-title":"J. Theor. Biol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12918-015-0221-8","article-title":"In silico evaluation and exploration of antibiotic tuberculosis treatment regimens","volume":"9","author":"Pienaar","year":"2015","journal-title":"BMC Syst. Biol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1128\/IAI.01438-15.Editor","article-title":"Multiscale Model of Mycobacterium tuberculosis Infection Maps Metabolite and Gene Perturbations to Granuloma Sterilization","volume":"84","author":"Pienaar","year":"2016","journal-title":"Infect. Immun."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1005650","article-title":"Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach","volume":"13","author":"Pienaar","year":"2017","journal-title":"PloS Comput. Biol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0196322","article-title":"Emergence and selection of isoniazid and rifampin resistance in tuberculosis granulomas","volume":"13","author":"Pienaar","year":"2018","journal-title":"PloS One"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/nm.3937","article-title":"The association between sterilizing activity and drug distribution into tuberculosis lesions","volume":"21","author":"Prideaux","year":"2015","journal-title":"Nat. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1071\/CH08240","article-title":"Prediction of tumour tissue diffusion coefficients of hypoxia-activated prodrugs from physicochemical parameters","volume":"61","author":"Pruijn","year":"2008","journal-title":"Aust. J. Chem."},{"key":"B47","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nri3211","article-title":"Revisiting the role of the granuloma in tuberculosis","volume":"12","author":"Ramakrishnan","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1021\/acsinfecdis.6b00051","article-title":"Prediction of Drug Penetration in Tuberculosis Lesions","volume":"2","author":"Sarathy","year":"2016","journal-title":"ACS Infect. Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.02266-17","article-title":"Extreme drug tolerance of mycobacterium tuberculosis in Caseum","volume":"62","author":"Sarathy","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"B50","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jtbi.2004.06.031","article-title":"Identifying control mechanisms of granuloma formation during M. tuberculosis infection using an agent-based model","volume":"231","author":"Segovia-Juarez","year":"2004","journal-title":"J. Theor. Biol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1164\/rccm.200411-1557OC","article-title":"The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis","volume":"172","author":"Sirgel","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.2174\/138161211797470192","article-title":"In Vitro and In Vivo Modeling of Tuberculosis Drugs and its Impact on Optimization of Doses and Regimens","volume":"17","author":"Srivastava","year":"2011","journal-title":"Curr. Pharm. Des."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0014014","article-title":"Patients' costs and cost-effectiveness of tuberculosis treatment in DOT and non-DOT facilities in Rio de Janeiro, Brazil","volume":"5","author":"Steffen","year":"2010","journal-title":"PloS One"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1093\/jac\/dky152","article-title":"Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis","volume":"73","author":"Stott","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002773","article-title":"Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization","volume":"16","author":"Strydom","year":"2019","journal-title":"PloS Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1093\/cid\/ciw471","article-title":"Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children with Tuberculosis: Bread Crumb Trails in Random Forests","volume":"63","author":"Swaminathan","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1164\/rccm.200206-626OC","article-title":"Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active Tuberculosis","volume":"167","author":"Yee","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B58","first-page":"1360","article-title":"Pharmacokinetics of ethambutol in children and adults with tuberculosis","volume":"8","author":"Zhu","year":"2004","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.00924-17","article-title":"Ethambutol Partitioning in Tuberculous Pulmonary Lesions Explains Its Clinical Efficacy","volume":"61","author":"Zimmerman","year":"2017","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00333\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T04:45:47Z","timestamp":1585025147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.00333\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,24]]},"references-count":59,"alternative-id":["10.3389\/fphar.2020.00333"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.00333","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,24]]},"article-number":"333"}}